

Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/SDD6D3C413A5EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: SDD6D3C413A5EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen tyrosine kinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Spleen tyrosine kinase inhibitors Understanding

Spleen tyrosine kinase inhibitors: Overview

Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk inhibitors are a new group of small molecule inhibitors targeting BCR-mediated signaling pathways.

Syk was recognized as a critical element in the BCR signaling pathway. Syk is also a

key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Syk along with other BCR signaling molecules, Bruton tyrosine kinase (BTK), PI3K delta (PI3K?), and tumor necrosis factor (TNF) superfamily receptors was also found to be involved in signal transduction independent from the BCR. Syk is expressed primarily in hematopoietic cells like B-cells, monocytes, macrophages, mast cells, and neutrophils. Syk was recognized to be a potential target for the treatment of various hematologic cancers, autoimmune disorders, and other inflammatory states.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Spleen tyrosine kinase inhibitors R&D. The therapies under development are focused on novel approaches for Spleen tyrosine kinase inhibitors.

Spleen tyrosine kinase inhibitors Emerging Drugs Chapters

This segment of the Spleen tyrosine kinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spleen tyrosine kinase inhibitors Emerging Drugs

Fostamatinib: Rigel Pharmaceuticals

Fostamatinib is a selective, oral spleen tyrosine kinase (SYK) inhibitor being evaluated for Autoimmune haemolytic anaemia, COVID-19 which is currently in Phase III stage of development and is being developed by Rigel Pharmaceuticals.

Entospletinib: Kronos Bio

Entospletinib (ENTO), is a selective inhibitor targeting SYK, a critical node in a dysregulated TRN within AML defined by persistent high expression of the transcription

factors HOXA9 and MEIS1 (HOX/MEIS). It is currently in Phase II stage of development for the treatment of Acute myeloid leukaemia and is being developed by Kronos Bio.

Further product details are provided in the report.....

Spleen tyrosine kinase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Spleen tyrosine kinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Spleen tyrosine kinase inhibitors

There are approx. 10+ key companies which are developing the Spleen tyrosine kinase inhibitors. The companies which have their Spleen tyrosine kinase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Rigel Pharmaceuticals.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Spleen tyrosine kinase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized

under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Spleen tyrosine kinase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Spleen tyrosine kinase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen tyrosine kinase inhibitors drugs.

Spleen tyrosine kinase inhibitors Report Insights

Spleen tyrosine kinase inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Spleen tyrosine kinase inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Spleen tyrosine kinase inhibitors drugs?

How many Spleen tyrosine kinase inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Spleen tyrosine kinase inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spleen tyrosine kinase inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Spleen tyrosine kinase inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Dermavant Sciences

Rigel Pharmaceuticals

Kronos Bio

Hutchison MediPharma

Hanmi Pharmaceutical

Genosco

Asana BioSciences

Key Products

Cerdulatinib

Fostamatinib

Entospletinib

Lanraplenib

HMPL-523

HM43239

SKI O 703

ASN002

Contents

- Introduction
- Executive Summary
- Spleen tyrosine kinase inhibitors: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- Fostamatinib: Rigel Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Entospletinib: Kronos Bio
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I/II)
 - Comparative Analysis
- HM43239: Hanmi Pharmaceutical
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Preclinical and Discovery Stage Products
 - Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Spleen tyrosine kinase inhibitors Key Companies

Spleen tyrosine kinase inhibitors Key Products

Spleen tyrosine kinase inhibitors- Unmet Needs

Spleen tyrosine kinase inhibitors- Market Drivers and Barriers

Spleen tyrosine kinase inhibitors- Future Perspectives and Conclusion

Spleen tyrosine kinase inhibitors Analyst Views

Spleen tyrosine kinase inhibitors Key Companies

Appendix

I would like to order

Product name: Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/SDD6D3C413A5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SDD6D3C413A5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970